RU2017131900A3 - - Google Patents

Download PDF

Info

Publication number
RU2017131900A3
RU2017131900A3 RU2017131900A RU2017131900A RU2017131900A3 RU 2017131900 A3 RU2017131900 A3 RU 2017131900A3 RU 2017131900 A RU2017131900 A RU 2017131900A RU 2017131900 A RU2017131900 A RU 2017131900A RU 2017131900 A3 RU2017131900 A3 RU 2017131900A3
Authority
RU
Russia
Application number
RU2017131900A
Other languages
Russian (ru)
Other versions
RU2723091C2 (ru
RU2017131900A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017131900A publication Critical patent/RU2017131900A/ru
Publication of RU2017131900A3 publication Critical patent/RU2017131900A3/ru
Application granted granted Critical
Publication of RU2723091C2 publication Critical patent/RU2723091C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/318Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181Peptide nucleic acid, PNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017131900A 2015-03-23 2016-02-12 Олигонуклеотидные последовательности, нацеленные на транскрипционный фактор tsc22d4, для лечения резистентности к инсулину RU2723091C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15160259.6A EP3072969A1 (en) 2015-03-23 2015-03-23 Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
EP15160259.6 2015-03-23
PCT/EP2016/053050 WO2016150618A1 (en) 2015-03-23 2016-02-12 Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance

Publications (3)

Publication Number Publication Date
RU2017131900A RU2017131900A (ru) 2019-04-23
RU2017131900A3 true RU2017131900A3 (enExample) 2019-06-10
RU2723091C2 RU2723091C2 (ru) 2020-06-08

Family

ID=52784935

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017131900A RU2723091C2 (ru) 2015-03-23 2016-02-12 Олигонуклеотидные последовательности, нацеленные на транскрипционный фактор tsc22d4, для лечения резистентности к инсулину

Country Status (12)

Country Link
US (2) US10676739B2 (enExample)
EP (2) EP3072969A1 (enExample)
JP (1) JP2018513841A (enExample)
KR (1) KR20170128348A (enExample)
CN (1) CN107278229A (enExample)
BR (1) BR112017016021A2 (enExample)
CA (1) CA2979115A1 (enExample)
DK (1) DK3274455T3 (enExample)
ES (1) ES2837085T3 (enExample)
MX (1) MX384193B (enExample)
RU (1) RU2723091C2 (enExample)
WO (1) WO2016150618A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7289510B2 (ja) * 2019-05-08 2023-06-12 国立大学法人高知大学 認知症治療薬のスクリーニング方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1206234A4 (en) * 1999-06-03 2005-06-01 Jessie L S Au METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド インスリン感受性/抵抗性、糖尿病および肥満におけるrbp4
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US7943306B2 (en) * 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
US20140227289A1 (en) 2011-05-13 2014-08-14 Stephen Michael Cohen Compounds and methods for treating insulin resistance syndrome
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
EP2816356A1 (en) 2013-06-17 2014-12-24 Ruprecht-Karls-Universität Heidelberg Treatment of insulin resistance through inhibitors of transcription factor TSC22D4
RU2573450C1 (ru) * 2014-08-11 2016-01-20 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ выявления генов-мишеней для диагностики и терапии лейкозов человека

Also Published As

Publication number Publication date
EP3274455B1 (en) 2020-10-14
BR112017016021A2 (pt) 2018-03-20
CA2979115A1 (en) 2016-09-29
WO2016150618A1 (en) 2016-09-29
KR20170128348A (ko) 2017-11-22
JP2018513841A (ja) 2018-05-31
EP3072969A1 (en) 2016-09-28
DK3274455T3 (da) 2020-12-14
US10676739B2 (en) 2020-06-09
US20180023078A1 (en) 2018-01-25
CN107278229A (zh) 2017-10-20
ES2837085T3 (es) 2021-06-29
MX384193B (es) 2025-03-12
RU2723091C2 (ru) 2020-06-08
RU2017131900A (ru) 2019-04-23
US20200255834A1 (en) 2020-08-13
US11053499B2 (en) 2021-07-06
EP3274455A1 (en) 2018-01-31
MX2017012231A (es) 2018-01-30

Similar Documents

Publication Publication Date Title
BR112018002648A2 (enExample)
BR112018004941A2 (enExample)
BR122019020650A2 (enExample)
RU2017131900A3 (enExample)
BR0007834B1 (enExample)
CN303066495S (enExample)
BR0007487B1 (enExample)
BR0007468B1 (enExample)
BR0006866B1 (enExample)
BR0006854B1 (enExample)
CN303072233S (enExample)
BR0002402B1 (enExample)
BR0002033B1 (enExample)
BR0006634B1 (enExample)
BR0007688B1 (enExample)
CN303070853S (enExample)
CN303069162S (enExample)
CN303067945S (enExample)
CN303067902S (enExample)
BR0008132B1 (enExample)
BRPI0501033B1 (enExample)
BR0001684B1 (enExample)
BR122014029722B1 (enExample)
BR0008604B1 (enExample)
BR0005085B1 (enExample)